Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.27 HKD
−159.91 M HKD
62.54 M HKD
157.36 M
About ASCLETIS PHARMA INC
Sector
Industry
CEO
Jinzi J. Wu
Website
Headquarters
Hangzhou
Founded
2013
FIGI
BBG00LG50P53
Ascletis Pharma, Inc. engages in the research and development, production, marketing, and sale of pharmaceutical products. The company was founded by Jinzi Jason Wu and is headquartered in Hangzhou, China.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of 1672 is 3.12 HKD — it has decreased by −0.95% in the past 24 hours. Watch ASCLETIS PHARMA INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on HKEX exchange ASCLETIS PHARMA INC stocks are traded under the ticker 1672.
1672 stock has risen by 40.54% compared to the previous week, the month change is a 74.30% rise, over the last year ASCLETIS PHARMA INC has showed a 97.47% increase.
1672 reached its all-time high on Aug 1, 2018 with the price of 14.90 HKD, and its all-time low was 0.76 HKD and was reached on Aug 23, 2024. View more price dynamics on 1672 chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
1672 stock is 5.33% volatile and has beta coefficient of 0.56. Track ASCLETIS PHARMA INC stock price on the chart and check out the list of the most volatile stocks — is ASCLETIS PHARMA INC there?
Today ASCLETIS PHARMA INC has the market capitalization of 3.16 B, it has increased by 32.35% over the last week.
Yes, you can track ASCLETIS PHARMA INC financials in yearly and quarterly reports right on TradingView.
ASCLETIS PHARMA INC is going to release the next earnings report on Mar 24, 2025. Keep track of upcoming events with our Earnings Calendar.
1672 earnings for the last half-year are −0.14 HKD per share, whereas the estimation was −0.13 HKD, resulting in a −8.10% surprise. The estimated earnings for the next half-year are −0.16 HKD per share. See more details about ASCLETIS PHARMA INC earnings.
ASCLETIS PHARMA INC revenue for the last half-year amounts to 0.00 HKD, matching the estimated figure, and no changes in revenue are expected for the next half-year.
1672 net income for the last half-year is −141.22 M HKD, while the previous report showed −138.45 M HKD of net income which accounts for −2.00% change. Track more ASCLETIS PHARMA INC financial stats to get the full picture.
No, 1672 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 26, 2024, the company has 219.00 employees. See our rating of the largest employees — is ASCLETIS PHARMA INC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ASCLETIS PHARMA INC EBITDA is −411.11 M HKD, and current EBITDA margin is −508.93%. See more stats in ASCLETIS PHARMA INC financial statements.
Like other stocks, 1672 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ASCLETIS PHARMA INC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ASCLETIS PHARMA INC technincal analysis shows the buy rating today, and its 1 week rating is strong buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ASCLETIS PHARMA INC stock shows the strong buy signal. See more of ASCLETIS PHARMA INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.